Skip to Content

Cencora Inc

COR: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$948.00DwyhwwDpqkbrdz

Cencora Continues to See Robust Growth From GLP-1s at the Cost of Margin Depression

Business Strategy and Outlook

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $200 billion in annual U.S. healthcare distribution sales, the company supplies roughly one third of the domestic drug distribution market. Its two close competitors are Cardinal Health and McKesson. Together, the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the U.S. market.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of COR so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center